Suma Project
-
Upload
sravanthirao -
Category
Documents
-
view
221 -
download
0
Transcript of Suma Project
-
8/8/2019 Suma Project
1/53
INTRODUCTION
-
8/8/2019 Suma Project
2/53
Finance is a blood of business. Financial management helps in achieving group
goals. IT reduces the cost and optimum utilization of funds and maximum efforts.
Financial management also referred to as corporate finance and managerial finance.
It involves planning, allocation of resources and control. There are three broad areas of
financial decision they are capital budgeting, capital structure and working capital
management and dividend decisions.
The financial activity plays a major role for success of an enterprise. For a proper
financial activity, the organizations need to evolve suitable and well-defined policies,
procedures and to manage the different specific function coming the financial activity. The
various policies and system relating to the finance wing hear to be covered comprehensively
and clearly in a policy document know as annual report which consists of balance sheet,
profit and lose account, financial statement, audit report etc. thus the annual report plays a
key role for guiding; the decision and actions of personnel of finance in a particular
direction for the success of financial function in an organization.
WORKING CAPITAL MANAGEMENT:
Working capital is one of the most important requirements of any business concern.
Working capital can be compared with the blood of human beings. As human cannot survive
without blood, in the same way no business concern can survive without capital.
Working capital management deals with maintaining the level of working capital to
optimum, because if a concern has inadequate opportunities and if the working capital is more
than required then the concern will lose money in the form of interest on the blocked funds.
Therefore working capital management plays a very important role in the profitability of
company.
To go deeper into the first of all the meaning of capital should be made clear. The
term working capital stands for that part of the capital, which is required for financing the
current needs of the company.
It is usually invested in raw materials stock (both finished and semi finished)
accounts receivable, securities and in cash. Capital in all these from is constantly being
converted into cash and this flow out again in exchange for other forms of working
-
8/8/2019 Suma Project
3/53
constantly turned over management of work in capital usually involves planning and
controlling these current asset.
NEED FOR WORKING CAPITAL
The basic objective of financial management is to maximize the shareholders wealth.
This is possible only when the company earns sufficient profits. The amount of such profits
largely depends upon the magnitude of sales. However do not into cash instantaneously. These
are always a time gap between the sale of goods and there actual realization in cash.
Working capital is required in order to sustain the sales activities in this adequate working
capital is not available for this period.
The company will not be in a position to purchase raw materials, pay wages and
oilier expenses required for manufacturing the goods. Therefore sufficient amount of working
capital is to be maintained at any point of time.
ADEQUACY OF WORKING CAPITAL
A firm must have adequate working capital i.e., as much as needed by the firm. It should
neither be excessive nor inadequate. Both the situations are harmful to the concern.
Excessive working capital means the firm has idle funds, which earn no profits for the firm
inadequate working capital ultimately results in production interruptions and lowering down
of the profitability.
It will be interesting to understand the relationship between working capital, risk andreturn in a manufacturing concern. It is generally accepted that higher levels of working
capital because the risk and have the potential of increasing the profitability also.
-
8/8/2019 Suma Project
4/53
OBJECTIVES OF THE STUDY
1. To study the existing system of working capital management in Ranbaxy
Laboratories Limited (Ranbaxy).
2. To analyze the financial performance of the company with reference to its working
capital components.
3. To know the liquidity position of the company.
4. To know the profitability position of the company using with ratios.
5. Suggesting a better way to improve management working capital.
SCOPE OF THE STUDY
1. The scope is limited to the operations of Ranbaxy Laboratories Limited (Ranbaxy).
2. The study mainly focuses on working capital management only.
3. The study focuses on ratios to find profitability position.
4. The study is confined to evaluation of the last 5 years annual reports.
4
-
8/8/2019 Suma Project
5/53
LIMITATIONS OF THE STUDY
1. The study was confined to a period of five years.
2. As most of the data is from secondary sources, to the results are not accurate.3. This analysis was confine to Ranbaxy Laboratories Limited (Ranbaxy) only.
4. The study was based on the annual reports of the Ranbaxy Laboratories Limited
(Ranbaxy).
5. The study period is restricted to 45 days.
COLLECTION OF THE DATA
This study adopts the methodology of collecting data from both sources primary and
secondary.
PRIMARY DATA
The primary data was collected by interacting with the finance manager and other
concerned executives at the administrative office of the Ranbaxy Laboratories Limited
(Ranbaxy).
SECONDARY DATA
All the secondary data used for the study have been extracted from the annual report,
manuals and other published materials of the Ranbaxy Laboratories Limited (Ranbaxy)
1) Annual reports and published generals from Ranbaxy Laboratories Limited
(Ranbaxy).
2) Information related the topic from text books of financial management.
3) Website www.ranbaxy.com
5
http://www.ranbaxy.com/http://www.ranbaxy.com/ -
8/8/2019 Suma Project
6/53
COMPANY PROFILE
6
-
8/8/2019 Suma Project
7/53
Ranbaxy Laboratories Limited (Ranbaxy), India's largest pharmaceutical company, is
an integrated, research based, international pharmaceutical company, producing a wide range
of quality, affordable generic medicines, trusted by healthcare professionals and patients
across geographies. Ranbaxy today has a presence in 23 of the top 25 pharmaceutical
markets of the world. The Company has a global footprint in 46 countries, world-class
manufacturing facilities in 7 countries and serves customers in over 125 countries.
In June 2008, Ranbaxy entered into an alliance with one of the largest Japanese
innovator companies, Daiichi Sankyo Company Ltd., to create an innovator and generic
pharmaceutical powerhouse. The combined entity now ranks among the top 20
pharmaceutical companies, globally. The transformational deal will place Ranbaxy in a
higher growth trajectory and it will emerge stronger in terms of its global reach and in its
capabilities in drug development and manufacturing.
Financials
Ranbaxy was incorporated in 1961 and went public in 1973. For the year 2009, the
Company recorded Global Sales of US $ 1519 Mn. The Company has a balanced mix of
revenues from emerging and developed markets that contribute 54% and 39% respectively.
In 2009, North America, the Company's largest market contributed sales of US $ 397 Mn,
followed by Europe garnering US $ 269 Mn and Asia clocking sales of around US $ 441 Mn.
Strategy
Ranbaxy is focused on increasing the momentum in the generics business in its key
markets through organic and inorganic growth routes. Growth is well spread across
geographies with focus on emerging markets. The Company continues to evaluate acquisition
opportunities in India, emerging and developed markets to strengthen its business andcompetitiveness. Ranbaxy has forayed into high growth potential segments like Biologics,
Oncology and Injectable. These new growth areas will add significant depth to the existing
product pipeline.
7
-
8/8/2019 Suma Project
8/53
R&D
Ranbaxy views its R&D capabilities as a vital component of its business strategy that
will provide a sustainable, long-term competitive advantage. The Company has a pool of
over 1,200 scientists engaged in path-breaking research.
Ranbaxy is among the few Indian pharmaceutical companies in India to have started
its research program in the late 70's, in support of its global ambitions. A first-of-its-kind
world class R&D centre was commissioned in 1994. Today, the Company's four multi-
disciplinary R&D centers at Gurgaon, in India, house dedicated facilities for generics
research and innovative research. The robust R&D environment for both drug discovery and
development reflects the Company's commitment to be a leader in the generics space offering
value added formulations based on its Novel Drug Delivery System (NDDS) and New
Chemical Entity (NCE) research capabilities.
The new drug research areas at Ranbaxy include anti-infectives, inflammatory /
respiratory, metabolic diseases, oncology, urology and anti-malaria therapies. Presently, the
Company has 8-10 programs including one Anti-malaria molecule for which Phase-III
clinical trials have commenced in India, Bangladesh and Thailand. The Company has signed
collaborative research programs with GSK and Merck.
NDDS focus is mainly on the development of NDA/ANDAs of oral controlled-
release products for the regulated markets. Ranbaxys first significant international successusing the NDDS technology platform came in September 1999, when the Company out-
licensed its first once-a-day formulation to a multinational com
8
-
8/8/2019 Suma Project
9/53
People
The Companys business philosophy based on delivering value to its stakeholders
constantly inspires its people to innovate, achieve excellence and set new global benchmarks.
Driven by the passion of its over 13,000 strong multicultural workforce comprising 50
nationalities, Ranbaxy continues to aggressively pursue its mission to become a Research-
based International Pharmaceutical Company.
BOARD OF DIRECTORS
At the helm of the entire operations is the experience and able direction of the people
who make it all happen, Ranbaxy acknowledges their inspiring stewardship and indefatigable
work.Dr. Tsutomu Une - Chairman, Non Executive & Non Independent Director
Mr.Atul Sobti - Chief Executive Officer & Managing Director
Mr. Takashi Shoda - Non Executive & Non Independent Director
Dr.Anthony H.Wild - Independent Director
Mr.Rajesh V. Shah - Independent Director
Mr.Akihiro Watanabe - Independent Director
Mr.Percy Shroff - Independent Director
EXECUTIVE TEAM
The Executive Committee is an apex body at Ranbaxy, that oversees Companys
global functioning. The group deliberates on important company issues steering it in the
right direction. The Committee ensures that all decisions are taken in the best interest of the
organization. This forum brings in different perspectives on a subject. Issues are discussed,
analyzed and concluded through exchange of ideas, reflecting the Companys philosophy of
participative management. It also facilitates the Companys compliance with the best
standards of Corporate Governance.
9
-
8/8/2019 Suma Project
10/53
Mr. Atul Sobti - Chief Executive Officer & Managing Director
Mr. Arun Sawhney - President Global Pharmaceuticals Business
Mr. Omesh Sethi - Chief Financial Officer
Mr. Ramesh L. Adige - President, Corporate Affairs & Global Corporate
Communications
Dr. Sudarshan K. Arora - President Research & Development
Mr. Bhagwat Yagnik - Head Global Human Resources
Mr. Hiroyuki Okuzawa - Head Global Synergy Project
Mr. ale Adkisson - Head Global Quality
Mr. Dipak Chattaraj - President, Corporate Development & Strategy
Mr. David Briskman - Chief Information Officer
Worldwide Operations
Global Pharma Companies are experiencing an ever changing landscape ripe withchallenges and opportunities. In this challenging environment Ranbaxy is enhancing its reach
leveraging its competitive advantages to become a top global player.
Driven by innovation and speed to market we focus on delivering world-class
generics at an affordable price. Our unwavering determination to achieve excellence leads us
to new global benchmarks. Our people have consistently risen above all challenges
maximized opportunities and positioned Ranbaxy as a leader in the global generics space.
Ranbaxys global footprint extends to 46 countries embracing different locales and
cultures to form a family of 50 nationalities with an intellectual pool of some of the best
minds in the world.
10
-
8/8/2019 Suma Project
11/53
Research and development
Ranbaxy views its R&D capabilities as a vital component of its business strategy that
will provide the company with a sustainable, long-term competitive advantage. The company
today has a pool of 1,200 scientists who are engaged in path-breaking research.
The robust R&D environment within the company for both drug discovery &
development reflects the Company's commitment to be a leader in the generics space and
offer value added formulations based on the Company's Novel Drug Delivery System
(NDDS) and New Chemical Entity (NCE) research outcomes.
NOVEL DRUG DELIVERY SYSTEMS (NDDS)
The NDDS research at Ranbaxy focuses on maximizing the overall therapeutic and
commercial value of commonly prescribed pharmaceutical formulations by enhancing their
performance and reducing their adverse event profile. Such innovation also helps to improve
the overall patient convenience and compliance
The company's NDDS focus is mainly on the development of New Drug Applications
(NDA) / Abbreviated New Drug Applications (ANDAs) of oral controlled- release productsfor the regulated markets. The Company's first significant international success using the
NDDS technology platform came in September 1999, when Ranbaxy licensed its once-a-day
Ciprofloxacin formulation on a worldwide basis to a multinational Company.
Ranbaxy's in-house NDDS programs are primarily focused on the oral segment.
Inhalation (patented devices) and trans-dermal (patented adhesive polymers) programs are
also being pursued through collaborations.
In the oral NDDS space, Ranbaxy has already developed four platform technologies
namely Gastro Retentive, Modified Matrix, Multi-particulate and AeroGel. Several products
leveraging these technologies have been successfully developed.
11
-
8/8/2019 Suma Project
12/53
NEW DRUG DISCOVERY RESEARCH (NDDR)
The Companys NDDR program focuses on select therapeutic segments of Infectious
diseases, Metabolic diseases, Inflammatory/ Respiratory disease and Oncology. Presently,
the Company has 8-10 programs in the area of NDDR.
The company has commenced Phase-III clinical trials for its new Anti-malaria
combination drug, Arterolane maleate + Piperaquine phosphate in India, Bangladesh and
Thailand.
The Companys potential drug candidate for Dyslipidemia RBx 10558, has been
successfully out-licensed to Pharmaceutical Product Development Inc. (PPD), a leading
global Contract Research Organization for clinical development for further development.
The Company is also profiling DPP-IV Inhibitors (Di-Peptidyl Peptidase IV
Inhibitors) for Type-2-diabetes, a selective Phosphodiesterase 4-b inhibitor for COPD and
Asthma, and a novel antibiotic antibacterial for Community Acquired Respiratory Tract
Infection.
The Company continues to forge ahead with its various research alliances, in order to
expedite its Drug Discovery program.
Significant progress has been made on two research programs, one each in the Anti-
infective and Respiratory segments, which are being pursued with GlaxoSmithKline (GSK).
Consequently, Ranbaxy and GSK have expanded the original agreement and Ranbaxy now
has the responsibility for advancing the selected compounds to proof of concept in man,
whereby total milestone payments, excluding royalties, could exceed over US $ 100 Mn.
Under an alliance with a leading academic institution in India, a number of medicinal plants are being evaluated as potential sources for novel pharmaceutical agents. The
Company also has collaborative research projects with other academic institutions in India in
the area of Respiratory and Infectious disease.
12
-
8/8/2019 Suma Project
13/53
R&D INFRASTRUCTURE
Ranbaxy is among the few Indian pharmaceutical companies in India to have
recognized the importance of Research & Development (R&D) and invested early in it. The
first research activity at Ranbaxy was initiated way back in the year 1973. Later whenRanbaxy drew its ambitious global plans, it embarked on R&D in a significant way by
establishing its first R&D centre in 1994.
Ranbaxy today has state-of-the-art multi-disciplinary centre at Gurgaon (near New
Delhi) in India, with dedicated facilities for generics research and innovative research.
The prowess of Indian scientists is widely acknowledged today and it is believed thatthe cost of developing a new drug in India can be one third to one fifth of doing the same, in
the developed world. It is a long term objective of Ranbaxy to build a proprietary
prescriptions business, based on its prowess in NDDS and NCE research.
Life at Ranbaxy
A career at Ranbaxy means an opportunity for ample learning & growth. It offers
avenues to work across the globe along side the finest minds. The Company offers a
challenging assignment, a world class working environment, professional management,
competitive salaries, stock options along with exceptional rewards.
If you have an appetite for challenges, we have an exciting career for you
Opportunities
The global spread of Ranbaxy and the blazing growth in business provides ample
opportunities for our employees to build careers in various fields. Opportunities have neverbeen a constraint for the deserving. We believe in employee growth that goes beyond vertical
movements and change in designations. Potential and performance are the pillars of career
progression at Ranbaxy. A robust development process supports this.
13
-
8/8/2019 Suma Project
14/53
Our managers will generally have the opportunity to live and work in different
countries; such international experience will help them better understand our complex
business and grow both personally and professionally.
Salary and Benefits
Salaries and other benefits in Ranbaxy are comparable with the best in the industry
and one can expect to be rewarded highly if the performance is consistently outstanding.
Group Life Insurance, Medical Insurance and Pension plans are a few examples of the
benefits we provide to our employees and their dependents with adequate financial protection
on long term basis.
Stock Ownership
The ownership in business is fundamental to personal progression, we encourage you
to take ownership of your investments.
Stock ownership is a part of the compensation for our managers early in their career
at Ranbaxy: you will see the business results straight in your pay slip.
Products
Using the finest R&D and Manufacturing facilities, Ranbaxy Laboratories Limited
manufacture and markets generic pharmaceuticals, value added generic pharmaceuticals,
branded generics, active Pharmaceuticals (API) and intermediates.
The Company remains focused on ascending the value chain in the marketing of
pharmaceutical substances and is determined to bring in increased revenues from dosage
forms sales. Ranbaxy's diverse product basket of over 5,000 SKUs available in over 125
countries worldwide, encompasses a wide therapeutic mix covering a majority of the chronic
and acute segments. Healthcare trends project that the chronic treatment segments will
outpace the acute treatment segments, primarily driven by a growing aging population and
dominance of lifestyle diseases. Our robust performance in Cardiovasculars, Central Nervous
14
-
8/8/2019 Suma Project
15/53
System, Respiratory, Dermatology, Orthopedics, Nutritionals and Urology segments, clearly
indicates that the Company has strengthened its presence in the fast-growing chronic and
lifestyle disease segments.
Top 20 Molecules
1. Simvastatin
2. AmoxiClav Potassium
3. Isotretinoin
4. Amoxycillin and Combinations
5. Ciprofloxacin and Combinations
6. Ketorolac Tromethamine
7. Omeprazole and Combinations
8. Cefuroxime Axetil
9. Cephalexin
10. Loratadine and Combinations
11. Clarithromycin
12. Ginseng+Vitamins
13. Diclofenac and Combinations
14. Ranitidine
15. Cefaclor
16. Cefpodoxime Proxetil
17. Efavirenz
18. Atorvastatin and Combinations
19. Fenofibrate
15
-
8/8/2019 Suma Project
16/53
20. Ofloxacin and Combinations
Manufacturing Facilities
An organizations capabilities and intent are strongly reflected in the product itmanufactures. In other words, the manufacturing competencies and facilities echo truly, the
R&D extent and the ability to implement it for the best of the market it targets.
RANBAXY possesses the manufacturing strengths that have established it as a
producer ofworld-class generics, branded generics and a major supplier of its range of
Active Pharmaceutical Ingredients for pharmaceutical products of companies worldwide.
Ranbaxy has world-class manufacturing facilities in 7 countries namely Ireland, India,
Malaysia, Nigeria, Romania, South Africa and USA. Its overseas facilities are designed to
cater to the requirements of the local regulatory bodies of that country while the Indian
facilities meet the requirements of all International Regulatory Agencies. Some of the
agencies such as MCA-UK, MCC-South Africa, FDA-USA and TGA-Australia, have
audited Ranbaxys manufacturing facilities for the compliance with international Good
Manufacturing Practices and have registered its products forsafety, quality and efficacy.
Collaborative Research
We believe that networking in R&D is key for accelerated progress. We have developed
major strengths in the areas of Chemical Research, Bio-equivalent generics and Novel Drug
Delivery System (NDDS). We have taken initiatives to create infrastructure and capabilities
in the area of New Drug Discovery Research. We have state-of-art research and development
Facilities at our R&D Center.
16
-
8/8/2019 Suma Project
17/53
Major Alliances/ Collaborations
1. Drug Discovery & Clinical Development - GlaxoSmithKline
2. Drug Discovery & Clinical Development Merck
3. Cipro OD Technology Out Licensed - Bayer
4. Statin molecule out licensed to PPD, USA
Our Focus
New Drug Discovery Research(NDDR)
1. Metabolic Diseases
2. Respiratory/ Inflammatory
3. Anti-Infectives
4. Oncology
We seek partners for -
Co-development in the above therapeutic areas for collaboration with companies /
universities / research institutions to undertake a discovery program starting from the
conceptual stage.
Novel Drug Delivery Systems (NDDS)
Our focus is on oral controlled release delivery systemsNDDS Technologies developed are on the following platforms
1. Multiparticulate
2. Modified matrix
3. Gastroretentive
17
-
8/8/2019 Suma Project
18/53
4. Aerogel
Pharma Research
For Value Added Dosage Forms
Current
1. Soft gel
2. Dispersible tabs / chewable tabs
3. Taste masking
4. Gels
5. Effervescent
18
-
8/8/2019 Suma Project
19/53
Theoretical Concepts
Working capital
Working capital is the firms holdings of current assets such as cash, receivable,
inventory and marketable securities. Every firm required working capital for its day-
to-day transactions such as purchasing raw material, for meeting salaries, wages,
rates, advertising etc.but there is much disagreement among various financial
authorities (financial managers, accountants, businessmen and economist) as to the
exact meaning of the term working capital. Working capital management is one of the
most important aspects of financial managers. Working capital management is
19
-
8/8/2019 Suma Project
20/53
concerned with the Problem that arise in attempting to manage the current assets, the
current Liabilities and the inter relationship between them. It also refers to
management of short time financing, negotiating favorable credit terms, controlling
the movement of cash; administration account receivables and monitoring theinvestment in inventories. The interaction between current assets and current
liabilities is therefore, the main theme of theory of working capital management.
The aim of working capital management is to manage the firms current assets and
current liabilities in such a way that a satisfactory level of working capital is
maintained otherwise, if the firm cannot maintain a satisfactory level of working
capital it may become insolvent. The current assets should be large enough to cover
current liabilities. The terms current assets refers to those assets, which can be
converted into cash within a short period.E.g.Inventery, B/Resource, Marketable
securities etc current liabilities are those liabilities are B/Products, Bank over draft
and outstanding expenses. The interaction between current assets assets and current
liabilities is therefore, in other words; the goal of working capital management is to
manage the current assets, current liabilities in such a way that an acceptable level of
net working capital is maintained.
CURRENT ASSETS
Cash and bank balances
Short loans advances
Bills receivable
Sundry debtors
Inventories such as,
Raw materials
Work-in-progress
20
-
8/8/2019 Suma Project
21/53
Finished goods
Prepaid expenses
Accrued incomes
Money receivable with in 12 months
The term working capital refers to the networking capital. Networking capital is the
excess of current assets over current liabilities. Current liabilities are those liabilities,
which are intended to be paid in the ordinary course of business within a short period
of normally one accounting one accounting year.
CURRENT LIABILITIES
Bills payable
Sundry creditors
Accounts payable
Short term borrowings
Dividend payable
Stationary liabilities
Accrued on outstanding expenses
Bank over draft
Provident fund due
Any other payment due with in 12months
Significance of working capital
The world in which real firms function is not perfect. It is characterized by the firms
considerable uncertainty regarding the demand, market price, quality and availability
of its own products and those of suppliers. This real world circumstances introduce
problems to the firm must deal. While the firm has many strategies available to
address this circumstance, strategies that utilize investment or financing with working
21
-
8/8/2019 Suma Project
22/53
capital account often offer a substantial advantage over the other techniques. The
importance of working capital management is reflected in fact that financial managers
spend a great deal of time in managing correct assets and current liabilities like. The
management of working capital plays an importance role in maintaining the financialhealth during the normal course of business. This critical role can be enunciated by
examine the flow of resources through the firm. By far the major flow is the working
capital cycle.
WORKING CAPITAL CYCLE
22
-
8/8/2019 Suma Project
23/53
This is the loop which starts at the cash and the marketable securities account, goes
trough the current account as direct labor and materials which are purchased and use
to produce inventory, which in turn is sold and generates accounts receivables, which
are finally collected to replenish cash. The major point to notice about this cycle is
that the turnover or velocity of resources through this loop is very high related to the
other inflows of the cash account.
CONCEPT OF WORKING CAPITAL
There are two concepts of working capital
Gross working capital
Net working capital
Gross working capital
23
-
8/8/2019 Suma Project
24/53
Gross working capital, simply called as working capital refers to the firms
investment in current assets. Current assets are the assets, which in ordinary course of
business can be converted into cash within an accounting year. Examples of current
assets are:
Cash and bank balances
Short term loans and advances
Bills receivables
Sundry debtors
Inventory
Prepaid expenses
Accrued incomes
Money receivable in 12 months
The gross working capital concept forces attention of two aspects of Current assets
management.
Optimum investment in current assets and
Financing of current assets.
The consideration of the level of investment in current assets should avoid two-danger
points-excessive and inadequate investment in current arranging funds to finance
current assets. When ever a need for working capital
Funds arise due to the increasing level of business activity or for any other reason
arrangement should be made quickly.
Net working capital
24
-
8/8/2019 Suma Project
25/53
Net working capital refers to the difference between the current assets and current
liabilities. Current liabilities are those claims of outsiders, which are accepted, to
mature for payment with an accounting year and include creditors, bills payable and
outstanding expenses.
Net working capital = current assets current liabilities
Net working capital can be positive or negative. A positive net working capital will
arise when current assets exceeds current liabilities. It is a quantitative concept.
Indicate the liquidity position of the firm and
Suggest the extent to which working capital needs may be financed
By permanent sources of funds.
TYPES OF WORKING CAPITAL:
Working capital can be divided into categories on the basis of time:
1. Permanent working capital.
2. Variable or temporary working capital.
Permanent working refers to minimum amount of investment in all current assets which
is required at all times to carryout minimum level of business activities in other words, it
represents the current assets required on a counting basis over the entire year the Tendon
committee has referred to this type of working capital as 'core current assets'.
Temporary working capital refers to that amount of working capital, which keeps on
fluctuating, from time to time on the basis of business activities. In other words it represents
additional currents assets required at different times operating year.
DETERMINING WORKING CAPITAL RAQUIREMENTS
25
-
8/8/2019 Suma Project
26/53
Prudent principal of financial management calls for holding small amount of working
capital as possible as possible. So long as the firm is not exposed to undue solvency risk. In
order to forecast the working capital requirements more objectively the financial manager often
makes use of percentage sales method, or operating cycle method. Operating cycle method call
for a precise estimation of the length of time (in week/ moths) required for converting the raw
materials into finished goods and holding the finished stock and debtors as well. Thus it
indirectly takes into account the policy the policy requirement of inventory and credit
management apart from the cash.
A wide variety of factors influence the total investment in working capital in an
enterprise. Significant amount them are discussed here with.
26
-
8/8/2019 Suma Project
27/53
1) NATURE OF BUSINESS
The nature of business has an important bearing on its working capital needs. Some
ventures like retail stores, construction companies etc., require on abundance of working capital.
In order cases, such as power generation and supply, the current assets play a minor and
secondary role.
2) MANUFACTURING CYCLE
An extended time span, between the raw material purchase and the completion of the
manufacturing process yielding the finished product, will obviously mean a larger tie-up of
funds in the form of enhanced working capital need. In such cases management should
endeavor to contain the intervening period and effect economy in working capital need, thoughprocess changes where possible, or though affective organizations and co-ordination at all
levels of enterprise activity to ensure that the operating cycle time is minimal. Frequent
changes in set-ups, waiting for materials, tools or instructions and accumulations of working-
in progress have the inevitable consequence of extending the cycle time freezing.
3) CREDIT TERMS TO CUSTOMERS
The credit terms to customers influence the working capital level by determining ihe
level of investment in block debts. Management's has to decide on suitable credit policy relevant
to each customer based on the merits of his case. Unduly liberal credit policies and slack
collection procedures or permissive attitude in the matter of collection of out standings can
look up funds that would otherwise be available for operating needs.
4) VAGRIES IN SUPPLY OF RAW MATERIAL
The sources of certain raw material are few and irregular and pose problems in the matter
of procurement and holding, using up more funds. Materials that are available only in certain
seasons have to be obtained and stored, in advance, for the lean months. The working capital
requirements, in such, instances, will show seasonal fluctuations.
27
-
8/8/2019 Suma Project
28/53
5) SHIFTS IN DEMAND FOR PRODUCTS
Some manufactured are subject to seasonal fluctuations in sales. In the interest of
utilization of capacity. Steady productions will have to be maintained, Independent of shifts on
demand for finished products. Goods inventories will, therefore, pile up during off-season and
will require increased amounts of working capital to be provided. Financial planning will have
to incorporate this pattern of funds requirement associated with steady production and seals.
6) PRODUCTION POLICIES
To off-set the problem of having to find funds to support the mounting inventory levels
of finished goods until they got off-loaded in the peak seasons. Some companies report to
diversification of activities, enabling production of the main product to follow the seasonalpattern of demand.
7) COMPETITIVE CONDITION
In a competitive market, wining and retaining customer satisfaction on a continuing
basis wills involve extra costs and present a variety of products will have to be manufactured
and stocked. This would mean higher levels of inventories in all stages and therefore, additional
working capital funds. More generous credit terms may have to be extended and the
investments in account receivable may have to be higher, requiring additional funds, the
degree of competition is thus an important factor influencing working capital requirements.
8) GROWTH AND EXPANSION PROGRAMMES
As business grows, additional working has to be found. In fact, the need for increased
working capital does not capital does not follow the growth in business activities, but
precedes it. Advance planning of working capital is thus a containing necessary for a growing
concern. Or else, the company may have substantial earning but little cash. With fast growth
they may be under constant financial pressure for external funds to reinforce internal
generation. Forward planning and continuous review therefore are absolutely for such
companies.
28
-
8/8/2019 Suma Project
29/53
-
8/8/2019 Suma Project
30/53
assets. The depreciation charges do not involve any cash outflow. Enhanced rates of
depreciation have effect of reducing profits corresponding, which in turn can help in holding
back distribution of -dividends. This process conserves cash. Depreciation policy, thus, exert,
influence on the status of working capital in the enterprise from time to time.
14) PRICE LIVEL CHANGES
Rapidly rising prices create the need for more funds for maintaining the present
volume off activity. For same levels off inventories, higher cash outlays are need. In an
inflationary setup, even operating expenses will grow for given levels of activity. Some
companies may be able to compensate parts of these cost increases through increase hi prices
levels on the working capital position will vary from company to company depending on the
nature off its. Operations and its standing in the market.
15) OPERATING EFFICIENCY
There is an obvious relationship between the operating efficiency of a company and its
working capital position. Waste elimination, improved coordinate to cut delays, efficiency in
operations and fuller utilization of resources is among the initiatives takes to avert erosion of
profits. They also have the effect of getting more out of a given volume of working capital.
Efficiency of operations accelerates the pace of the cycle, and improves the working turnover. It
releases the pressure on working capital by improving profitability and aiding added internal
generation of funds.
30
-
8/8/2019 Suma Project
31/53
Analysis of Data & Interpretation
31
-
8/8/2019 Suma Project
32/53
STATEMENT SHOWING CHANGE IN WORKING CAPITAL
FOR THE YEAR 2004 AND 2005
(Rs in Millions)
Particulars
Year ended as 31st
MarchWorking Capital
2004 2005 Increase Decrease
Current Assests:
Inventory
Sundry Debtors
Cash and Bank Balance
Other Current Assests
Loans and Advances
8963.38
7846.89
372.60
805.08
5094.25
8909.33
8066.18
1165.93
1179.16
3333.08
- - - - - -
219.29
793.33
374.08
- - - - - -
1024.57
938.18
54.05
- - - - - -
- - - - - -
- - - - - -
1761.17
- - - - - -
- - - - - -
1534.23
Total (A) 23082.20 22653.68
Current Liabilities
Liabilities
Provisions
8307.37
5078.10
7282.80
4139.92
Total (B) 13385.47 11422.72
Networking Capital (A-B) 9696.73 11230.96
Increase in Working Capital 1534.23
Total 11230.96 11230.96 3349.45 3349.45
32
-
8/8/2019 Suma Project
33/53
INTERPRETATION:
The stock has been decreased by Rs.54.05 (millions) due to less purchases.The total current
assets were decreased by Rs.428.52 (millions)because of decreased in loans & advances.Net
working capital increased by Rs.1534.23 (millions).The total current liabilities were
decreased by Rs.1962.75 (millions) because of increased in other current assets.The overall
financial performance of the company was satisfactory.
33
8963.38
23082.2
4822.63
13385.47
0
5000
10000
15000
20000
25000
inventory current Asset Net WorkingCapital Current Liabilities
2004
2005
Working Caital
-
8/8/2019 Suma Project
34/53
STATEMENT SHOWING CHANGE IN WORKING CAPITAL
FOR THE YEAR 2005 AND 2006
(Rs in Millions)
ParticularsYear ended as 31st March Working Capital
2005 2006 Increase Decrease
Current Assests:
Inventory
Sundry Debtors
Cash and Bank Balance
Other Current Assests
Loans and Advances
8909.33
8066.18
1165.93
1179.16
3333.08
16115.52
15716.33
2951.16
978.05
5343.03
7206.19
7650.15
1785.23
- - - - - -
2009.95
- - - - - -
- - - - - -
- - - - - -
- - - - - -
- - - - - -
201.11
- - - - - -
4845.06
1328.79
12276.56
Total (A) 22653.68 41104.09
Current Liabilities
Liabilities
Provisions
7282.80
4139.92
12127.86
5468.71
Total (B) 11422.72 17596.57
Networking Capital (A-B) 11230.96 23507.52
Increase in Working Capital 17230.96
Total 23507.52 23507.52 18651.22 18651.22
34
-
8/8/2019 Suma Project
35/53
INTERPRETATION:
The stock has been increased by Rs.7206.19 (millions) due to more purchases.The total
current assets were increased by Rs.18450.41 (millions) because of increased in cash & Bank
Balances. The total current liabilities were increased by Rs.6173.85 (millions) because of
increased in other current liabilities.Net working capital increased by Rs.12276.56 (millions)
due to increased in current assets.The overall financial performance of the company was
satisfactory.
35
16115.52
41104.09
17596.5123507.52
0
10000
20000
30000
40000
50000
60000
70000
80000
90000
Inventory Current Assests Current
Liabilities
Net Working
Capital
Working Capital
2006
2005
-
8/8/2019 Suma Project
36/53
STATEMENT SHOWING CHANGE IN WORKING CAPITAL
FOR THE YEAR 2006 AND 2007
(Rs in Millions)
ParticularsYear ended as 31st March Working Capital
2006 2007 Increase Decrease
Current Assests:
Inventory
Sundry Debtors
Cash and Bank Balance
Other Current Assests
Loans and Advances
16115.52
15716.33
2951.16
978.05
5343.03
9760.71
8829.07
1804.50
1020.25
6886.29
- - - - - -
- - - - - -
- - - - - -
42.20
1543.26
3796.66
- - - - - -
10919.32
6354.81
6887.26
1146.66
- - - - - -
- - - - - -
- - - - - -
1912.71
Total (A) 41104.09 28300.82
Current Liabilities
Liabilities
Provisions
12127.86
5468.71
8331.20
7381.42
Total (B) 17596.57 15712.62
Networking Capital (A-B) 23507.52 12588.20
Increase in Working Capital 10919.32
Total 23507.52 23507.52 16301.44 16301.44
36
16115.52
41104.09
17596.5723507.52
9760.71
28300.82
15712.6212588.26354.81
1280.27
1883.95
10919.32
0
10000
20000
30000
40000
50000
60000
70000
80000
Inventory Current Assests CurrentLiabilities Net WorkingCapital
Working Capital
2007
2006
-
8/8/2019 Suma Project
37/53
INTERPRETATION:
The stock has been decreased by Rs.6354.01 (millions) due to less purchases.The total
current assets were decreased by Rs.128.03 (millions) because of decreased in Bank Balances
& cash.The total current liabilities were decreased by Rs.1883.95 (millions) because of other
current liabilities were decreased.Net working capital decreased by Rs.10919.32
(millions)The overall financial performance of the company was not satisfactory
37
-
8/8/2019 Suma Project
38/53
STATEMENT SHOWING CHANGE IN WORKING CAPITAL
FOR THE YEAR 2007 AND 2008
(Rs in Millions)
ParticularsYear ended as 31st March Working Capital
2007 2008 Increase Decrease
Current Assests:
Inventory
Sundry Debtors
Cash and Bank Balance
Other Current Assests
Loans and Advances
9760.71
8829.07
1804.50
1020.25
6886.29
11985.19
10245.35
19349.39
1345.53
8559.78
2224.48
1416.28
17544.89
325.28
1673.49
- - - - - -
69.47
3828.93
- - - - - -
- - - - - -
- - - - - -
- - - - - -
- - - - - -
27082.82
- - - - - -
Total (A) 28300.82 51485.24
Current Liabilities
Liabilities
Provisions
8331.20
7381.42
35414.02
7311.95
Total (B) 15712.62 42725.97Networking Capital (A-B) 12588.20 8759.27
Increase in Working Capital 3828.93
Total 12588.20 12588.20 27082.82 27082.82
389760.71
28300.8215712.62 12588.2
11985.19
51485.24
42725.97
8759.272224.48
23184.42
27013.35
3828.93
0
20000
40000
60000
80000
100000
120000
Inventory Current Assests CurrentLiabilities Net WorkingCapital
Working Capital
2008
2007
-
8/8/2019 Suma Project
39/53
INTERPRETATION:
The stock has been increased by Rs.2224.48 (millions) due to more purchases.The total
current assets were increased by Rs.23184.42 (millions) because of increased the cash &
Bank Balances. The total current liabilities were increased by Rs.27013.35 (millions) because
of increased in other current liabilities.Net working capital decreased by Rs.3878.93
(millions) due to increased in current liabilities.The overall financial performance of the
company was not satisfactory.
39
-
8/8/2019 Suma Project
40/53
STATEMENT SHOWING CHANGE IN WORKING CAPITAL
FOR THE YEAR 2008 AND 2009
(Rs in Millions)
ParticularsYear ended as 31st March Working Capital
2008 2009 Increase Decrease
Current Assests:
Inventory
Sundry Debtors
Cash and Bank Balance
Other Current Assests
Loans and Advances
11985.19
10245.35
19349.39
1345.53
8559.78
12304.82
15346.48
7541.24
9648.16
1558.74
319.63
5101.13
- - - - - -
8302.63
- - - - - -
8855.58
- - - - - -
- - - - - -
- - - - - -
11808.15
- - - - - -
7001.04
- - - - - -
318.39
3451.40
Total (A) 51485.24 46399.49
Current Liabilities
Liabilities
Provisions
35414.02
7311.95
26558.44
7630.34
Total (B) 42725.97 34188.78
Networking Capital (A-B) 8759.27 12210.66
Increase in Working Capital 3451.40
Total 12210.66 12210.661 22578.98 22578.98
40
-
8/8/2019 Suma Project
41/53
INTERPRETATION:
The stock has been increased by Rs.319.63 (millions) due to more purchases.The total
current assets were decreased by Rs.5085.80 (millions) because of decreased in cash & Bank
Balances and loans & advances.The total current liabilities were decreased by Rs.8537.19
(millions) because of decreased current liabilities.Net working capital has been increased by
Rs. 345.14 (millions).The overall financial performance of the company was satisfactory.
41
11985.19
51485.2442725.97
8759.27
12304.82
46399.49
34188.78
12210.66
319.63
5085.8
8537.19
3451.4
0
20000
40000
60000
80000
100000
120000
Inventory Current Assests CurrentLiabilities
Net WorkingCapital
Working Capital
2009
2008
-
8/8/2019 Suma Project
42/53
RATIO ANALYSIS
CURRENT RATIO:
Current ratio may be defined as the relationship between the current assets and the
current liabilities. This ratio is also known as working capital ratio, it measures of general
liquidity and is most widely used to make the analysis of a short term financial position or
liquidity of a firm. It is calculated by dividing the total current assets by total of the current
liabilities. Thus
Current AssetsCurrent Ratio =
Current Liabilities
YEARCURRENT
ASSETS
CURRENT
LIABILITESRATIO
2004-05 22653.68 11422.72 0.64:1
2005-06 41104.09 17596.57 2.34:1
2006-07 28300.82 15712.62 1.80:1
2007-08 51485.24 42725.97 1.20:1
2008-09 46399.44 34188.78 1.36:1
Average 143590.22 145410.77 0.99:1
42
-
8/8/2019 Suma Project
43/53
INTERPRETATION:
The average current ratio of the five years is 0.99:1 it can observed that the
current ratio of RAMBAXY Laboratories Limited is less than the standard ration i.e.,
2:1. Hence the current of the company was not satisfactory.
43
-
8/8/2019 Suma Project
44/53
QUICK RATIO:
The term liquidity refers to the ability of a firm to pay its short term obligation as and
when they become due. Liquid ratio may be defined as the relationship between liquid assets
and current or liquid liabilities. An asset is said to be liquid if it can be converted into cash
within a short period without loss of value.
Quick AssetsQuick Ratio=
Current Liabilities
YEARQUICK
ASSETS
CURRENT
LIABILITESRATIO
2004-05 13744.35 11422.72 1.20:1
2005-06 24988.57 17596.57 1.42:1
2006-07 18540.11 15712.62 1.17:1
2007-08 39500.05 42725.97 0.93:1
2008-09 34094.62 34188.78 0.99:1
Average 130867.73 145410.77 1.07:1
44
-
8/8/2019 Suma Project
45/53
INTERPRETATION:
The average quick of five years is 1.07:1 it can be observed that the quick ratio
of RAMBAXY is here the standard ratio i.e. 1:1. Hence the quick ratio of the
company was satisfactory.
45
-
8/8/2019 Suma Project
46/53
NET PROFIT RATIO:
The net profits are obtained after deducting income tax and generally non operating
expenses and incomes are excluded from the net profits for calculating this ratio. The
symptoms such as interest on investment out side the business. Profit and sales are fixed
assets and losses on sales of fixed assets.
Net Profit after taxNet Profit Ratio= X 100
Net sales
YEARNET PROFIT
AFTER TAXNET SALES RATIO
2004-05 2236.98 8741.76 25.59
2005-06 5103.60 13866.94 36.81
2006-07 6177.20 12043.98 51.29
2007-08 10448.07 9532.36 109.60
2008-09 5719.84 11145.96 51.32
Average 29685.69 55331.00 53.65
46
-
8/8/2019 Suma Project
47/53
INTERPRETATION:
The average net profit ratio of five years 53.65 of RAMBAXY it can be
observed that ne profit ratio of the company was satisfactory.
47
-
8/8/2019 Suma Project
48/53
GROSS PROFIT RATIO:
This ratio establishes relationship between gross profit and sales to measures the
relative efficiency of the corporation and to reflect it pricing policies it indicates the position
of trading results.
GROSS PROFITGross profit Ratio= X 100
NET SALES
YEARNET PROFIT
AFTER TAXNET SALES RATIO
2004-05 2236.98 35697.69 62.66
2005-06 5153.60 61915.78 83.23
2006-07 4246.56 74617.56 56.91
2007-08 2162.69 45031.48 48.02
2008-09 5719.84 47974.89 119.2
Average 19519.67 264937.40 73.67
48
-
8/8/2019 Suma Project
49/53
INTERPRETATION:
The average gross profit ratio of five years 73.67 of RAMBAXY it can be
observed that gross profit ratio of the company is very high. Higher the gross profit
greater the operating efficiency so gross profit ratio was satisfactory.
49
-
8/8/2019 Suma Project
50/53
DEBIT EQUITY RATIO:
Debt equity ratio also known as external equity ratio is calculated to measure the
relative claims of outsiders and the share holders against the company assets. This ratio
indicate the relationship the outsiders funds and share holders fund usually this ratio is
calculated by dividing long term depth with share holder funds.
External EquitiesDebt Equity Ratio=
Internal Equities
YEAREXTERNAL
EQUITIES
INTERNAL
EQUITIESRATIO
2004-05 10298.04 23770.19 0.44
2005-06 39556.19 25849.91 1.53
2006-07 35030.28 25372.16 1.38
2007-08 37253.71 35411.07 1.05
2008-09 33483.80 41346.05 0.81
Average 155622.02 151749.38 1.02
50
-
8/8/2019 Suma Project
51/53
INTERPRETATION:
Average debt equity of five years 1.07:1 it can be observed that the debt equity the
ratio of RAMBAXY was more than standard ratio i.e, 1:1 hence the debt equity was not
satisfactory.
CONCLUSIONS
51
-
8/8/2019 Suma Project
52/53
1. The financial position of the company was satisfactory.
2. The liquidity position of the company was satisfactory.
3. The cash and bank balances were maintaining sufficiently.
4. The operating expenses was increasing year to year.
5. The working capital management of the company was satisfactory.
6. The inventory levels of the company was satisfactory.
52
-
8/8/2019 Suma Project
53/53
SUGGESTIONS
1. The company should decrease their operating expences, inorder to increase the
profits.
2. The networking capital of the company was fluctuations, so maintain standard.
3. The company should decrease the bank balance inorder to increase the efficiency.
4. The company has to maintain sufficient current assets.
5. The company has to maintain the results and surplus to expand its business
operations.
6. The company must increase its share capitals, which was not consistant over the
period of study.